PRTA - Prothena Corporation plc

PRTA - Prothena Corporation plc

https://www.prothena.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Prothena Down 40% Year to Date: What Lies Ahead for the Stock?

Zacks Commentary • 4 days, 3 hours ago • score: 0.26

Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.

Prothena ( PRTA ) Up 17.6% Since Last Earnings Report: Can It Continue?

Zacks Commentary • 1 week, 5 days ago • score: 0.28

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study - Eli Lilly ( NYSE:LLY ) , Biogen ( NASDAQ:BIIB )

Benzinga • 2 weeks, 4 days ago • score: 0.19

PRX012 showed 27.47 CL amyloid reduction at 400 mg, nearing FDA-defined thresholds. ARIA-E rates reached up to 41.7%, higher than those seen with Leqembi or Lilly drugs. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day

Prothena ( PRTA ) Reports Q2 Loss, Lags Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.07

Prothena (PRTA) delivered earnings and revenue surprises of -67.57% and -79.20%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics ( PTCT ) Surges 11.2%: Is This an Indication of Further Gains?

Zacks Commentary • 1 month, 2 weeks ago

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The company is headquartered in Dublin, Ireland.

52W High

$22.71

52W Low

$4.32

MA Status:

50D: Above 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.04

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

28.99

EV/EBITDA (<8 favorable)

-3.58

EV/Revenue (<3 favorable)

9.53

P/S (TTM) (<3 favorable)

44.51

P/B (<3 favorable)

1.42

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

18.66%

Institutions (25–75% balanced)

79.76%

Shares Outstanding

53,830,000

Float

40,091,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

10,341,000

Gross Profit (TTM)

-181,882,000

EPS (TTM)

-5.62

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-11.77%

ROE (TTM) (>15% strong)

-0.67%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.97

Momentum

Bearish momentum

Value

0.2330

Previous

0.2700

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025